These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 20129059)

  • 1. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
    Brownell JE; Sintchak MD; Gavin JM; Liao H; Bruzzese FJ; Bump NJ; Soucy TA; Milhollen MA; Yang X; Burkhardt AL; Ma J; Loke HK; Lingaraj T; Wu D; Hamman KB; Spelman JJ; Cullis CA; Langston SP; Vyskocil S; Sells TB; Mallender WD; Visiers I; Li P; Claiborne CF; Rolfe M; Bolen JB; Dick LR
    Mol Cell; 2010 Jan; 37(1):102-11. PubMed ID: 20129059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute quantification of E1, ubiquitin-like proteins and Nedd8-MLN4924 adduct by mass spectrometry.
    Yang X; Brownell JE; Xu Q; Zhu F; Ma J; Loke HK; Rollins N; Soucy TA; Minissale JJ; Thomas MP; Mallender WD; Dick LR; Li P; Liao H
    Cell Biochem Biophys; 2013 Sep; 67(1):139-47. PubMed ID: 23754621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
    Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
    PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
    Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
    Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
    Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
    Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme.
    Lee HW; Nam SK; Choi WJ; Kim HO; Jeong LS
    J Org Chem; 2011 May; 76(9):3557-61. PubMed ID: 21417215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
    Nawrocki ST; Griffin P; Kelly KR; Carew JS
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
    Milhollen MA; Thomas MP; Narayanan U; Traore T; Riceberg J; Amidon BS; Bence NF; Bolen JB; Brownell J; Dick LR; Loke HK; McDonald AA; Ma J; Manfredi MG; Sells TB; Sintchak MD; Yang X; Xu Q; Koenig EM; Gavin JM; Smith PG
    Cancer Cell; 2012 Mar; 21(3):388-401. PubMed ID: 22439935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.
    Milhollen MA; Narayanan U; Soucy TA; Veiby PO; Smith PG; Amidon B
    Cancer Res; 2011 Apr; 71(8):3042-51. PubMed ID: 21487042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
    Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
    Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dynamics investigation on the poor sensitivity of A171T mutant NEDD8-activating enzyme (NAE) for MLN4924.
    Verma S; Singh A; Mishra A
    J Biomol Struct Dyn; 2014; 32(7):1064-73. PubMed ID: 23782099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues.
    Chen JJ; Tsu CA; Gavin JM; Milhollen MA; Bruzzese FJ; Mallender WD; Sintchak MD; Bump NJ; Yang X; Ma J; Loke HK; Xu Q; Li P; Bence NF; Brownell JE; Dick LR
    J Biol Chem; 2011 Nov; 286(47):40867-77. PubMed ID: 21969368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.
    El-Mesery M; Anany MA; Hazem SH; Shaker ME
    Arch Biochem Biophys; 2020 Sep; 691():108513. PubMed ID: 32721435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
    Luo Z; Pan Y; Jeong LS; Liu J; Jia L
    Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
    Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
    Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.